Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab

Rheumatol Int. 2002 Nov;22(6):227-32. doi: 10.1007/s00296-002-0246-3. Epub 2002 Sep 4.


Objective: The aim was to evaluate the efficacy and safety of multiple infusions with achimeric, anti-tumor necrosis factor (TNF)alpha monoclonal antibody (infliximab) in patients with psoriatic arthritis (PsA) and psoriasis vulgaris.

Methods: Over 22 weeks, nine patients with both active psoriasis and PsA received five infusions of 3 mg/kg infliximab. The endpoints included changes in the swollen and tender joints counts, American College of Rheumatology (ACR) preliminary criteria for improvement response rates 20, 50, and 70, and improvement in the psoriasis area and severity index (PASI).

Results: The swollen count (SJC) and tender joint count (TJC) fell from means of 5.33+/-2.22 and 17.80+/-4.21 to 1.44+/-1.09 and 9.77+/-0.92, respectively, by week 2 ( P=0.02, P=0.02). This benefit was sustained through week 22 (2.00+/-1.12/7.77+/-3.68, P=0.05/ P=0.002). The ACR 20/50/70 response was achieved in 89%/56%/22% of cases. The mean PASI score improved from 19.04+/-5.41 to 4.91+/-2.51 ( P=0.002).

Conclusion: Multiple infusions of infliximab were effective and well tolerated in patients with active psoriasis and PsA.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / physiopathology
  • Female
  • Humans
  • Infliximab
  • Joints / physiopathology
  • Male
  • Middle Aged
  • Pain Measurement
  • Psoriasis / drug therapy
  • Psoriasis / pathology
  • Severity of Illness Index
  • Skin / drug effects
  • Skin / pathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / immunology*


  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab